Target intelligence / Profile preview

CCDC13 antisense RNA 2 (CCDC13-AS2)

Target
CCDC13-AS2
Molecular classification
Long non-coding RNA (lncRNA), Antisense RNA, Intergenic RNA
01

Overview

CCDC13 antisense RNA 2 (CCDC13-AS2) is a human long non-coding RNA affiliated with the lncRNA class and categorized as an antisense transcript, meaning it is transcribed in the opposite direction relative to its sense (protein-coding) gene partner. Like other antisense lncRNAs, CCDC13-AS2 may be involved in the regulation of gene expression at the level of chromatin remodeling, transcriptional interference, alternative splicing, and post-transcriptional interactions. Antisense lncRNAs have been shown to play important roles in epigenetic regulation, imprinting, and in some cases, in cancer biology; however, there is no direct evidence that CCDC13-AS2 itself is a validated disease biomarker or therapeutic target. Its gene is located at human chromosome locus as annotated by the NCBI Gene database (Gene ID: 729083) and in Ensembl (ENSG00000225611). There is currently no established direct link to drug targeting, biomarker status, or safety concern specifically regarding CCDC13-AS2.

Other names
LINC02158long intergenic non-protein coding RNA 2158CCDC13-AS2
02

Mechanism of action

Not applicable (no drugs directly target CCDC13-AS2; general lncRNA-targeting strategies may include antisense oligonucleotides or RNA interference, but not for this specific RNA)

03

Biological functions

Regulation of gene expressionChromatin remodelingAlternative splicing regulationmiRNA spongingEpigenetic regulation
04

Disease associations

Cancer (broadly implicated in cancer biology and regulation)Other (possible roles in imprinting, response to therapy, but not well characterized for this RNA specifically)

Beyond the preview

Go deeper on CCDC13 antisense RNA 2 (CCDC13-AS2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CCDC13 antisense RNA 2 (CCDC13-AS2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call